ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47

ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47

Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHO, Ho, JOHNSON, Jeffrey, HADJIVASSILIOU, Haralambos, SUN, Jeonghoon, ZHU, Dan, ACHARYA, Sharmistha, HARIHARAN, Kandasamy
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CHO, Ho
JOHNSON, Jeffrey
HADJIVASSILIOU, Haralambos
SUN, Jeonghoon
ZHU, Dan
ACHARYA, Sharmistha
HARIHARAN, Kandasamy
description Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2022162330A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2022162330A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2022162330A13</originalsourceid><addsrcrecordid>eNrjZLBz9XP39HN1DfL0c1fwd1Nw9AOiEE8nf5dIBTf_IIWQUF__IN1gVx9X5xDPMFcFJ08_F6hSZxcTcx4G1rTEnOJUXijNzaDs5hri7KGbWpAfn1pckJicmpdaEh8abGRgZGRoZmRsbOBoaEycKgDM6Sp9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47</title><source>esp@cenet</source><creator>CHO, Ho ; JOHNSON, Jeffrey ; HADJIVASSILIOU, Haralambos ; SUN, Jeonghoon ; ZHU, Dan ; ACHARYA, Sharmistha ; HARIHARAN, Kandasamy</creator><creatorcontrib>CHO, Ho ; JOHNSON, Jeffrey ; HADJIVASSILIOU, Haralambos ; SUN, Jeonghoon ; ZHU, Dan ; ACHARYA, Sharmistha ; HARIHARAN, Kandasamy</creatorcontrib><description>Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220526&amp;DB=EPODOC&amp;CC=US&amp;NR=2022162330A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220526&amp;DB=EPODOC&amp;CC=US&amp;NR=2022162330A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHO, Ho</creatorcontrib><creatorcontrib>JOHNSON, Jeffrey</creatorcontrib><creatorcontrib>HADJIVASSILIOU, Haralambos</creatorcontrib><creatorcontrib>SUN, Jeonghoon</creatorcontrib><creatorcontrib>ZHU, Dan</creatorcontrib><creatorcontrib>ACHARYA, Sharmistha</creatorcontrib><creatorcontrib>HARIHARAN, Kandasamy</creatorcontrib><title>ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47</title><description>Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBz9XP39HN1DfL0c1fwd1Nw9AOiEE8nf5dIBTf_IIWQUF__IN1gVx9X5xDPMFcFJ08_F6hSZxcTcx4G1rTEnOJUXijNzaDs5hri7KGbWpAfn1pckJicmpdaEh8abGRgZGRoZmRsbOBoaEycKgDM6Sp9</recordid><startdate>20220526</startdate><enddate>20220526</enddate><creator>CHO, Ho</creator><creator>JOHNSON, Jeffrey</creator><creator>HADJIVASSILIOU, Haralambos</creator><creator>SUN, Jeonghoon</creator><creator>ZHU, Dan</creator><creator>ACHARYA, Sharmistha</creator><creator>HARIHARAN, Kandasamy</creator><scope>EVB</scope></search><sort><creationdate>20220526</creationdate><title>ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47</title><author>CHO, Ho ; JOHNSON, Jeffrey ; HADJIVASSILIOU, Haralambos ; SUN, Jeonghoon ; ZHU, Dan ; ACHARYA, Sharmistha ; HARIHARAN, Kandasamy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2022162330A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CHO, Ho</creatorcontrib><creatorcontrib>JOHNSON, Jeffrey</creatorcontrib><creatorcontrib>HADJIVASSILIOU, Haralambos</creatorcontrib><creatorcontrib>SUN, Jeonghoon</creatorcontrib><creatorcontrib>ZHU, Dan</creatorcontrib><creatorcontrib>ACHARYA, Sharmistha</creatorcontrib><creatorcontrib>HARIHARAN, Kandasamy</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHO, Ho</au><au>JOHNSON, Jeffrey</au><au>HADJIVASSILIOU, Haralambos</au><au>SUN, Jeonghoon</au><au>ZHU, Dan</au><au>ACHARYA, Sharmistha</au><au>HARIHARAN, Kandasamy</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47</title><date>2022-05-26</date><risdate>2022</risdate><abstract>Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2022162330A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A57%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHO,%20Ho&rft.date=2022-05-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2022162330A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true